

Points of Contact

Markus Reich
Managing Partner



m.reich@crossequity.ch

Dr Michael Petersen
Managing Partner



m.petersen@crossequity.ch

Company Calendar

27 August 2014
Cross Summer Bash

9 September 2014
Advisory Board Meeting

1 October 2014
Annual General Meeting

Recent Developments



Four investee companies
One add-on acquisition
One divestment

70% of Fund Commitments called
2.7x Gross Money Multiple
47% Gross IRR



Markus Arigoni has been appointed as new CEO of Micromacinazione. Markus Arigoni gained broad experience in the biomaterial- and medical device industry with substantial sales responsibility in EMEA and APAC. Before joining Micromacinazione, he was Business Unit Director China with Johnson & Johnson.

Selected Portfolio Highlights



World leader in post-condensation technology for PET

- YTD EBITDA well above budget
- Stand-alone measures well advanced
- Active project pipeline, but conversion rate below expectation



European leader in micro-nization technologies for the pharmaceutical industry

- EBITDA doubled since entry in June 2012
- Expansion of global sales force on track
- Refinance planned for Q3 2014



European leader in branded lifestyle products for the private bathroom

- Robust performance against difficult market environment in 2013
- Procurement cost savings well advanced
- New brand concept implemented

Market and Dealflow

- The European private equity market has seen a constant improvement during the past year. The outlook for 2014 is positive, in Germany the growth rate is expected to double compared to 2013. The focus this year is expected to be on acquiring new investments, after developing portfolio companies in 2013.
- Availability of leverage further improved in the DACH region at competitive margins. Transaction debt ratios increased to >50% for the first time since 2007. Unitranche financings are increasing.
- Cross continues to source the majority of its dealflow through proprietary angles.